Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 104

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial

Chastre, Jean, François, Bruno, Bourgeois, Marc, Komnos, Apostolos, Ferrer, Ricard, Rahav, Galia, De Schryver, Nicolas, Lepape, Alain, Koksal, Iftihar, Luyt, Charles-Edouard, Sánchez-García, Miguel, Torres, Antoni, Eggimann, Philippe, Koulenti, Despoina, Holland, Thomas L., Ali, Omar, Shoemaker, Kathryn, Ren, Pin, Sauser, Julien, Ruzin, Alexey, Tabor, David E., Akhgar, Ahmad, Wu, Yuling, Jiang, Yu, DiGiandomenico, Antonio, Colbert, Susan, Vandamme, Drieke, Coenjaerts, Frank, Malhotra-Kumar, Surbhi, Timbermont, Leen, Oliver, Antonio, Barraud, Olivier, Bellamy, Terramika, Bonten, Marc, Goossens, Herman, Reisner, Colin, Esser, Mark T., Jafri, Hasan S., The COMBACTE-MAGNET EVADE Study Group, Joannidis, Michael, Klimscha, Walter, De Waele, Elisabeth, Devriendt, Jacques, Huberlant, Vincent, Depuydt, Pieter, Van Boxstael, Sam, Peric, Mladen, Kopic, Jasminka, Hanauer, Michal, Hruby, Tomas, Sramek, Vladimir, Svoboda, Petr, Vymazal, Tomas, Novacek, Martin, Annane, Djillali, Mira, Jean-Paul, Souweine, Bertrand, Dequin, Pierre-François, Meziani, Ferhat, Stephan, François, Nseir, Saadalla, Gibot, Sebastien, Schwebel, Carole, Plantefeve, Gaetan, Diehl, Jean-Luc, Richard, Christian, Lamer, Christian, Klouche, Kada, Jaber, Samir, Zakynthinos, Epaminondas, Filntisis, Georgios, Zakynthinos, Spyros, Koutsoukou, Antonia, Saroglou, Georgios, Nikolaou, Charikleia, Vlachogianni, Glykeria, Pnevmatikos, Ioannis, Mandragos, Konstantinos, Kremer, Ildiko, Rozgonyi, Zsolt Dezso, Marjanek, Zsuzsa, Martin-Loeches, Ignacio, Singer, Pierre, Van Heerden, Vernon, Carmeli, Yehuda, Povoa, Pedro, Seoane, Antonio Alvarez, Moura, Pedro, Gonzalez, Filipe, Ramirez, Paula, Marti, Antonio Torres, Roca, Ricard Ferrer, Oteiza, Lorena, Escudero, Dolores, Piacentini, Enrique, Vera, Paula, Tamayo, Luis, Gallego, Miguel Angel Gonzalez, Canas, Borja Suberviola, Figueira, Iglesias, Leon, Rafael, Korten, Volkan, Akova, Murat, Wyncoll, Duncan, Whitehouse, Tony, Hopkins, Phil, Sim, Malcolm, Golan, Yoav, Zervos, Marcus, Vazquez, Jose, Cherabuddi, Kartikeya, Smulian, George, Rouphael, Nadine, Welker, James, Sims, Mathew, Van Duin, David, McCarthy, Todd, Polk, Christopher·2022·Critical Care

Abstract

Background: Ventilator-associated pneumonia caused by Pseudomonas aeruginosa (PA) in hospitalised patients is associated with high mortality. The effectiveness of the bivalent, bispecific mAb MEDI3902 (gremubamab) in preventing PA nosocomial pneumonia was assessed in PA-colonised mechanically ventilated subjects. Methods: EVADE (NCT02696902) was a phase 2, randomised, parallel-group, double-blind, placebo-controlled study in Europe, Turkey, Israel, and the USA. Subjects ≥ 18 years old, mechanically ventilated, tracheally colonised with PA, and without new-onset pneumonia, were randomised (1:1:1) to MEDI3902 500, 1500 mg (single intravenous dose), or placebo. The primary efficacy endpoint was the incidence of nosocomial PA pneumonia through 21 days post-dose in MEDI3902 1500 mg versus placebo, determined by an independent adjudication committee. Results: Even if the initial sample size was not reached because of low recruitment, 188 subjects were randomised (MEDI3902 500/1500 mg: n = 16/87; placebo: n = 85) between 13 April 2016 and 17 October 2019. Out of these, 184 were dosed (MEDI3902 500/1500 mg: n = 16/85; placebo: n = 83), comprising the modified intent-to-treat set. Enrolment in the 500 mg arm was discontinued due to pharmacokinetic data demonstrating low MEDI3902 serum concentrations. Subsequently, enrolled subjects were randomised (1:1) to MEDI3902 1500 mg or placebo. PA pneumonia was confirmed in 22.4% ( n = 19/85) of MEDI3902 1500 mg recipients and in 18.1% ( n = 15/83) of placebo recipients (relative risk reduction [RRR]: − 23.7%; 80% confidence interval [CI] − 83.8%, 16.8%; p = 0.49). At 21 days post-1500 mg dose, the mean (standard deviation) serum MEDI3902 concentration was 9.46 (7.91) μg/mL, with 80.6% ( n = 58/72) subjects achieving concentrations > 1.7 μg/mL, a level associated with improved outcome in animal models. Treatment-emergent adverse event incidence was similar between groups. Conclusions: The bivalent, bispecific monoclonal antibody MEDI3902 (gremubamab) did not reduce PA nosocomial pneumonia incidence in PA-colonised mechanically ventilated subjects. Trial registration Registered on Clinicaltrials.gov ( NCT02696902 ) on 11th February 2016 and on EudraCT ( 2015-001706-34 ) on 7th March 2016.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13054-022-04204-9

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 25

  1. Ramírez-Estrada S, Borgatta B, Rello J. Pseudomonas aeruginosa ventilator-associated pneumonia management. Infect Drug Resist. 2016;9:7–18.
  2. Kollef MH, Chastre J, Fagon JY, Francois B, Niederman MS, Rello J, et al. Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crit Care Med. 2014;42(10):2178–87. · DOI · Paper page
  3. Micek ST, Wunderink RG, Kollef MH, Chen C, Rello J, Chastre J, et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit Care. 2015;19(1):219. · DOI · Paper page
  4. Tumbarello M, De Pascale G, Trecarichi EM, Spanu T, Antonicelli F, Maviglia R, et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med. 2013;39(4):682–92. · DOI · Paper page
  5. François B, Luyt CE, Dugard A, Wolff M, Diehl JL, Jaber S, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med. 2012;40(8):2320–6. · DOI · Paper page
  6. François B, Chastre J, Eggiman P, Laterre PF, Torres A, Sanchez M, et al. The SAATELLITE and EVADE clinical studies within the COMBACTE consortium: a public-private collaborative effort in designing and performing clinical trials for novel antibacterial drugs to prevent nosocomial pneumonia. Clin Infect Dis. 2016;63(Suppl. 2):S46-51. · DOI
  7. Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Dellinger RP, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014;42(8):1749–55. · DOI · Paper page
  8. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388–416. · DOI · Paper page
  9. Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019;37(1):177–92. · DOI · Paper page
  10. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–111. · DOI · Paper page
  11. Tümmler B. Emerging therapies against infections with Pseudomonas aeruginosa. F1000Res. 2019;8(F1000 Faculty Rev-1371):1371. · DOI
  12. Que YA, Lazar H, Wolff M, François B, Laterre PF, Mercier E, et al. Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis. 2014;33(10):1861–7. · doi:10.1007/s10096-014-2156-1
  13. DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014;6(262):262ra155. · DOI · Paper page
  14. Ali SO, Yu XQ, Robbie GJ, Wu Y, Shoemaker K, Yu L, et al. Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. Clin Microbiol Infect. 2019;25(5):629.e1–.e6. · DOI · Paper page
  15. Le HN, Tran VG, Vu TTT, Gras E, Le VTM, Pinheiro MG, et al. Treatment efficacy of MEDI3902 in Pseudomonas aeruginosa bloodstream infection and acute pneumonia rabbit models. Antimicrob Agents Chemother. 2019;63(8):e00710-e719. · DOI
  16. Le HN, Quetz JS, Tran VG, Le VTM, Aguiar-Alves F, Pinheiro MG, et al. MEDI3902 correlates of protection against severe Pseudomonas aeruginosa pneumonia in a rabbit acute pneumonia model. Antimicrob Agents Chemother. 2018;62(5):e02565-e2617. · DOI
  17. Francois B, Jafri HS, Chastre J, Sanchez-Garcia M, Eggimann P, Dequin PF, et al. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. Lancet Infect Dis. 2021;21(9):1313–23. · DOI
  18. Yu XQ, Robbie GJ, Wu Y, Esser MT, Jensen K, Schwartz HI, et al. Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-staphylococcus aureus alpha-toxin human monoclonal antibody. Healthy Adults Antimicrob Agents Chemother. 2017;61(1):e01020-e1116.
  19. O’Leary-Kelley C, Bawel-Brinkley K. Nutrition support protocols: enhancing delivery of enteral nutrition. Crit Care Nurse. 2017;37(2):e15–23. · DOI
  20. Zeng J, Wang CT, Zhang FS, Qi F, Wang SF, Ma S, et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial. Int Care Med. 2016;42(6):1018–28. · DOI · Paper page
  21. Marik PE, Stephenson E. The ability of procalcitonin, lactate, white blood cell count and neutrophil-lymphocyte count ratio to predict blood stream infection. Analysis of a large database. J Crit Care. 2020;60:135–9. · DOI
  22. Gregoriano C, Heilmann E, Molitor A, Schuetz P. Role of procalcitonin use in the management of sepsis. J Thorac Dis. 2020;12(Suppl 1):S5–15. · DOI · Paper page
  23. Huang Z, Fu Z, Huang W, Huang K. Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: a meta-analysis. Am J Emerg Med. 2020;38(3):641–7. · DOI · Paper page
  24. Melsen WG, Rovers MM, Groenwold RHH, Bergmans DC, Camus C, Bauer TT, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013;13(8):665–71. · DOI · Paper page
  25. Group RC. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet (Lond Engl). 2022;399(10325):665–76. · DOI · Paper page

Cited by

See all 104

Metadata

Authors
Chastre, J., François, B., Bourgeois, M., Komnos, A., Ferrer, R., Rahav, G., De Schryver, N., Lepape, A., Koksal, I., Luyt, C.-E., Sánchez-García, M., Torres, A., Eggimann, P., Koulenti, D., Holland, T. L., Ali, O., Shoemaker, K., Ren, P., Sauser, J., Ruzin, A., Tabor, D. E., Akhgar, A., Wu, Y., Jiang, Y., DiGiandomenico, A., Colbert, S., Vandamme, D., Coenjaerts, F., Malhotra-Kumar, S., Timbermont, L., Oliver, A., Barraud, O., Bellamy, T., Bonten, M., Goossens, H., Reisner, C., Esser, M. T., Jafri, H. S., The COMBACTE-MAGNET EVADE Study Group, Joannidis, M., Klimscha, W., De Waele, E., Devriendt, J., Huberlant, V., Depuydt, P., Van Boxstael, S., Peric, M., Kopic, J., Hanauer, M., Hruby, T., Sramek, V., Svoboda, P., Vymazal, T., Novacek, M., Annane, D., Mira, J.-P., Souweine, B., Dequin, P.-F., Meziani, F., Stephan, F., Nseir, S., Gibot, S., Schwebel, C., Plantefeve, G., Diehl, J.-L., Richard, C., Lamer, C., Klouche, K., Jaber, S., Zakynthinos, E., Filntisis, G., Zakynthinos, S., Koutsoukou, A., Saroglou, G., Nikolaou, C., Vlachogianni, G., Pnevmatikos, I., Mandragos, K., Kremer, I., Rozgonyi, Z. D., Marjanek, Z., Martin-Loeches, I., Singer, P., Van Heerden, V., Carmeli, Y., Povoa, P., Seoane, A. A., Moura, P., Gonzalez, F., Ramirez, P., Marti, A. T., Roca, R. F., Oteiza, L., Escudero, D., Piacentini, E., Vera, P., Tamayo, L., Gallego, M. A. G., Canas, B. S., Figueira, I., Leon, R., Korten, V., Akova, M., Wyncoll, D., Whitehouse, T., Hopkins, P., Sim, M., Golan, Y., Zervos, M., Vazquez, J., Cherabuddi, K., Smulian, G., Rouphael, N., Welker, J., Sims, M., Van Duin, D., McCarthy, T., & Polk, C.
Venue
Critical Care
Published
2022-11-15
Volume
26
Issue
1
ISSN
1364-8535
Cited by
104
References
3
Language
en
Licence
Funders
Innovative Medicine Initiative Joint Undertaking (115737)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. https://app.cochat.ai/papers/10.1186/s13054-022-04204-9
The paper
Chastre, J., François, B., Bourgeois, M., Komnos, A., Ferrer, R., Rahav, G., De Schryver, N., Lepape, A., Koksal, I., Luyt, C.-E., Sánchez-García, M., Torres, A., Eggimann, P., Koulenti, D., Holland, T. L., Ali, O., Shoemaker, K., Ren, P., Sauser, J., . . . Polk, C. (2022). Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Critical Care. https://doi.org/10.1186/s13054-022-04204-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.